Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 gram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 gram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Malta - English - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 g - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;  ;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime;   - powder for injection - 250 mg - active: ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime   excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime;  ;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 582mg equivalent to 500 mg ceftazidime;  ;   - powder for injection - 500 mg - active: ceftazidime pentahydrate 582mg equivalent to 500 mg ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - ceftazidime - powder for solution for injection - 500 milligram(s) - third-generation cephalosporins; ceftazidime